All the news Showing 10 of 135 articles from: TreatmentGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources 10 patients safely receive hepatitis C-infected lungs in new clinical trial CTV / 14 June 2018 Switching to TAF improves safety in people with hepatitis B with kidney and bone risk factors Liz Highleyman / 04 May 2018 People with risk factors for tenofovir toxicity who switched from tenofovir disoproxil fumarate (TDF; Viread) to the new tenofovir alafenamide (TAF; Vemlidy) maintained hepatitis B virus (HBV) suppression and showed evidence of improved kidney and ... Hepatitis B capsid inhibitors look promising in early studies Liz Highleyman / 18 April 2018 Two experimental drugs that interfere with assembly of the hepatitis B virus (HBV) capsid and prevent production of functional new virus demonstrated good safety and promising antiviral activity in early clinical trials, according ... Tenofovir DF does not reduce the risk of mother-to-child hepatitis B transmission Liz Highleyman / 14 March 2018 Mothers who took tenofovir disoproxil fumarate (Viread) during pregnancy did not have a significantly lower risk of transmitting hepatitis B virus (HBV) to their infants compared with those who used ... 'Virus-cracking' molecules advance fight against hepatitis B Science Daily / 07 February 2018 Treatment that interferes with viral assembly shows promise for hepatitis B Liz Highleyman / 18 December 2017 JNJ-56136379, an experimental drug that interferes with assembly of the hepatitis B virus (HBV) capsid, demonstrated potent antiviral activity in an early clinical trial, researchers reported at the recent 2017 AASLD Liver Meeting in ... RNA interference therapy lowers viral biomarker in people with hepatitis B Liz Highleyman / 14 December 2017 ARB-1467, a novel type of treatment for hepatitis B, reduced levels of hepatitis B surface antigen (HBsAg) when used alone, and it may play a role in combination therapy to cure the ... Immune modulator inarigivir looks promising for people with hepatitis B Liz Highleyman / 12 December 2017 Inarigivir, or SB 9200, an immune-modulating drug that has a dual mechanism of action against hepatitis B virus (HBV), reduced levels of HBV DNA, RNA and antigens, and potency was ... TAF for hepatitis B improves kidney function and bone loss Liz Highleyman / 30 November 2017 Tenofovir alafenamide (TAF) remains effective against hepatitis B virus (HBV) for 96 weeks, with no resistance detected, according to studies presented at the 2017 AASLD Liver Meeting last month in ... REP 2139 combination therapy leads to functional control of hepatitis B virus Liz Highleyman / 29 November 2017 A majority of people with chronic hepatitis B treated with a nucleic acid polymer (REP 2139 or REP 2165) plus tenofovir and pegylated interferon were able to achieve 'functional control' of hepatitis B ... ← Prev1...34567...14Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Transmission and prevention Diagnosis and monitoring Disease course and symptoms Treatment HIV and HBV HCV and HBV Hepatitis delta Living with HBV Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive